TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC
出版年份 2022 全文链接
标题
TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC
作者
关键词
-
出版物
Cell Death & Disease
Volume 13, Issue 5, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-12
DOI
10.1038/s41419-022-04909-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PBK/TOPK: A Therapeutic Target Worthy of Attention
- (2021) Ziping Han et al. Cells
- New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
- (2021) Yu He et al. PHARMACOLOGICAL RESEARCH
- Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma
- (2020) Sarah Yenser Wood et al. Future Oncology
- Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
- (2020) Ufuk Degirmenci et al. Cells
- PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma
- (2020) YOHEI SEKINO et al. ANTICANCER RESEARCH
- Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma
- (2020) Xiu-Lan Liu et al. MEDICINE
- Molecular targeting of renal cell carcinoma by an oral combination
- (2020) Andre R. Jordan et al. Oncogenesis
- Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy
- (2020) Ying Wang et al. Molecular Cancer
- Extracellular vesicles transmitted miR‐31‐5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma
- (2019) Jinlan He et al. INTERNATIONAL JOURNAL OF CANCER
- The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
- (2019) W. Marston Linehan et al. Nature Reviews Urology
- Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin
- (2019) Roger Gilabert-Oriol et al. Drug Delivery and Translational Research
- Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
- (2019) Huan Deng et al. Frontiers in Oncology
- Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells
- (2019) Juanjuan Xiao et al. Cell Death & Disease
- Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models
- (2019) Andrew T. Stefka et al. Cancer Medicine
- The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis
- (2017) Tatyana A. Zykova et al. EBioMedicine
- Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma
- (2016) Z Xu et al. ONCOGENE
- TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun
- (2016) Ying Li et al. Oncotarget
- Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon
- (2016) Juanjuan Xiao et al. Oncotarget
- Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase
- (2016) Xiaoyu Zeng et al. Oncotarget
- A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting
- (2015) Mayer N. Fishman et al. PLoS One
- TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis
- (2014) Y. Matsuo et al. Science Translational Medicine
- Sorafenib for the treatment of renal cancer
- (2012) Dirk Strumberg EXPERT OPINION ON PHARMACOTHERAPY
- MET: a promising anticancer therapeutic target
- (2012) Solange Peters et al. Nature Reviews Clinical Oncology
- TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer
- (2011) M-C Shih et al. ONCOGENE
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Hypoxia: A Link between Fibrogenesis, Angiogenesis, and Carcinogenesis in Liver Disease
- (2010) Olivier Rosmorduc et al. SEMINARS IN LIVER DISEASE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now